{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:33:00Z","timestamp":1761514380563,"version":"build-2065373602"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.berh.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T11:56:08Z","timestamp":1555502168000},"page":"887-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Myositis in clinical practice\u2014relevance of new antibodies"],"prefix":"10.1016","volume":"32","author":[{"given":"Siamak","family":"Moghadam-Kia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.03.012_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.03.012_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.012_bib4","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.012_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2019.03.012_bib6","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2019.03.012_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib8","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"9","key":"10.1016\/j.berh.2019.03.012_bib9","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10 Suppl","key":"10.1016\/j.berh.2019.03.012_bib11","article-title":"A\u00a0consensus hybrid definition using a Conjoint analysis is proposed as response criteria for minimal and moderate improvement in adult polymyositis and dermatomyositis clinical trials","volume":"64","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.012_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.012_bib14","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.012_bib15","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League against rheumatism\/American College of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.berh.2019.03.012_bib17","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","article-title":"Amyopathic dermatomyositis (dermatomyositis sin\u00e9myositis): presentation of six new cases and review of the literature","volume":"24","author":"Euwer","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib21","first-page":"128","article-title":"The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum","volume":"31","author":"Ghazi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11926-996-0025-3","article-title":"Myositis specific autoantibodies","volume":"8","author":"Targoff","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2019.03.012_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2019.03.012_bib24","first-page":"2017","article-title":"Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies","volume":"18","author":"Akintayo","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2019.03.012_bib25","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-017-3598-5","article-title":"\u201cHiker's feet\u201d: a novel cutaneous finding in the inflammatory myopathies","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib26","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar3275","article-title":"Novel autoantibodies and clinical phenotypes in adult and juvenile myositis","volume":"13","author":"Betteridge","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.03.012_bib28","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.22506","article-title":"Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase","volume":"56","author":"Hirakata","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","article-title":"Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies","volume":"46","author":"Sato","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib30","first-page":"S312","article-title":"Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract)","volume":"52","author":"Hashish","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2010.05.008","article-title":"Pulmonary manifestations of the idiopathic inflammatory myopathies","volume":"31","author":"Kalluri","year":"2010","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.berh.2019.03.012_bib32","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2019.03.012_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.03.012_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.012_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A\u00a0longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.berh.2019.03.012_bib38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.humpath.2014.01.018","article-title":"The pulmonary histopathologic manifestations of the anti-PL7\/antithreonyl transfer RNA synthetase syndrome","volume":"45","author":"Yousem","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.berh.2019.03.012_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jclinpath-2014-202367","article-title":"Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy","volume":"67","author":"Schneider","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.berh.2019.03.012_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5858\/arpa.2013-0667-OA","article-title":"The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome","volume":"139","author":"Schneider","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.berh.2019.03.012_bib41","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib42","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib46","first-page":"30","article-title":"[Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody]","volume":"49","author":"Nagata","year":"2011","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.berh.2019.03.012_bib47","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.berh.2019.03.012_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib50","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2019.03.012_bib51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-Melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.berh.2019.03.012_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2169\/internalmedicine.56.6856","article-title":"An atypical clinical course of anti-MDA5 antibody-positive interstitial lung disease in a patient with three deteriorations in 9 years","volume":"56","author":"Sato","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.berh.2019.03.012_bib54","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Pt 8","key":"10.1016\/j.berh.2019.03.012_bib55","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.berh.2019.03.012_bib56","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.berh.2019.03.012_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.berh.2019.03.012_bib59","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib60","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.012_bib61","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A\u00a0novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2015.02.042","article-title":"Statin induced necrotizing autoimmune myopathy","volume":"351","author":"Babu","year":"2015","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.berh.2019.03.012_bib64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.012_bib65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-Induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.berh.2019.03.012_bib66","first-page":"S98","volume":"64","author":"Malik","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.berh.2019.03.012_bib68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/ajrccm\/141.3.727","article-title":"Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings","volume":"141","author":"Tazelaar","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.berh.2019.03.012_bib70","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archdermatol.2010.134","article-title":"Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations","volume":"146","author":"Morganroth","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2019.03.012_bib71","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.berh.2019.03.012_bib72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.berh.2019.03.012_bib73","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2214\/AJR.16.17121","article-title":"CT findings, radiologic-pathologic correlation, and imaging predictors of survival for patients with interstitial pneumonia with autoimmune features","volume":"208","author":"Chung","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 5","key":"10.1016\/j.berh.2019.03.012_bib74","first-page":"v1","article-title":"Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.berh.2019.03.012_bib75","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.berh.2019.03.012_bib76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1573398X11666150619182624","article-title":"Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD)","volume":"11","author":"Mittoo","year":"2015","journal-title":"Curr Respir Med Rev"},{"key":"10.1016\/j.berh.2019.03.012_bib77","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-4615-4857-7_54","article-title":"The effect of methylprednisolone pulse therapy in polymyositis\/dermatomyositis","volume":"455","author":"Bolosiu","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.berh.2019.03.012_bib78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.berh.2019.03.012_bib79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.berh.2019.03.012_bib80","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.berh.2019.03.012_bib81","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A\u00a0retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.berh.2019.03.012_bib82","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib83","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/14397595.2013.874762","article-title":"Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis","volume":"24","author":"Tsuchiya","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib84","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","article-title":"Polymyositis-dermatomyositis-associated interstitial lung disease","volume":"164","author":"Douglas","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.berh.2019.03.012_bib85","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.03.012_bib86","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.012_bib87","first-page":"188","article-title":"The effects of FK506 on refractory inflammatory myopathies","volume":"111","author":"Mitsui","year":"2011","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.berh.2019.03.012_bib88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.berh.2019.03.012_bib90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2019.03.012_bib92","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.03.012_bib93","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.012_bib94","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.berh.2019.03.012_bib95","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","article-title":"Abatacept as a successful therapy for myositis\u2014a case-based review","volume":"34","author":"Kerola","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2019.03.012_bib96","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:04Z","timestamp":1761499144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521694219300476"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.012","relation":{},"ISSN":["1521-6942"],"issn-type":[{"type":"print","value":"1521-6942"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myositis in clinical practice\u2014relevance of new antibodies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}